Sells VOQUEZNA medicines for gastrointestinal conditions, including reflux disease and H. pylori infection, to U.S. patients through healthcare channels.
10-K for FY2025, filed Feb 26, 2026We are a commercial-stage biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal, or GI…View ↗
All of our revenue is derived from the sale of three products in the United States: VOQUEZNA (vonoprazan) tablets which are approved for…View ↗
In the United States, we sell our products primarily to pharmaceutical wholesale distributors and select pharmacies, which in turn…View ↗
Pharmaceutical wholesalers and select pharmacies pay for VOQUEZNA products when the products are delivered; those buyers resell them to pharmacies and healthcare providers.
10-K for FY2025, filed Feb 26, 2026Pursuant to Accounting Standards Codification 606, Revenue from Contracts with Customers, or ASC 606, the Company recognizes revenue when a…View ↗
The Company sells its product to its customers, primarily wholesale distributors, in the United States. The Company’s customers…View ↗
In the United States, we sell our products primarily to pharmaceutical wholesale distributors and select pharmacies, which in turn…View ↗
$175.1M
10-K for FY2025, filed Feb 26, 2026
$175.1M ↗
The company sells mainly to pharmaceutical wholesale distributors and select pharmacies, which resell the products to retail pharmacies, institutions, clinics and patients.
10-K for FY2025, filed Feb 26, 2026In the United States, we sell our products primarily to pharmaceutical wholesale distributors and select pharmacies, which in turn…View ↗
No. It lost $221.2M in FY2025.
10-Q for Q3 FY2026, filed Oct 29, 2026
−$13.9MView ↗
8-K, filed Jul 30, 2026
Net Revenue $ 310–325 million $ 320–345 millionView ↗
From development to U.S. sales
The older report described Phathom as focused on developing and commercializing treatments, with its products and candidate still in development. The latest report describes an active U.S. business selling VOQUEZNA products and developing further treatments.
10-K for FY2022, filed Feb 28, 2023 10-K for FY2025, filed Feb 26, 2026We are a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Our…View ↗
Competes with Sebela Pharmaceuticals, Daewoong Pharmaceutical, Cinclus Pharma Holding AB, and RedHill Biopharma
10-K for FY2025, filed Feb 26, 2026We are also aware of several PCABs in development in the United States and in our licensed territories outside the United States, that, if…View ↗
Loading...